Reclassification of marijuana opens doors for much-needed medical research … – The Conversation
The DEA's proposed reclassification of cannabis from Schedule I to Schedule III represents a watershed moment for medical research opportunities in cannabis medicine. This regulatory shift will remove decades-old barriers to rigorous clinical studies…
“We need to get educated”: lessons from physicians certifying cannabis as an alternative to opioids in the Illinois Opioid Alternative Patient Program.
A survey of Illinois physicians participating in the state's Opioid Alternative Patient Program revealed that cannabis as opioid alternative physician education remains a critical need. Even early adopter clinicians emphasized educational gaps as a…
Drug policy and culture: A cross-national comparative study using Hofstede’s index.
Cross-national analysis of 25 countries reveals that cultural factors in cannabis policy significantly influence national drug policy frameworks. Countries with lower power distance and uncertainty avoidance demonstrate more progressive approaches to…
What Federal Cannabis Rescheduling Means for Care
Cannabis Schedule III rescheduling marks a major shift in how cannabis is classified and understood at the federal level. This change begins to align policy with clinical reality, affecting research, documentation, and patient access. Cannabis Schedule…
Contentious legality in decentralized governance: The rise and decline of cannabis social clubs in Spain.
A comprehensive policy analysis reveals how Spanish cannabis social clubs legal framework exploited legal ambiguities to create community-based alternatives to illicit markets. The study demonstrates how grassroots activism and strategic legal…
What the DOJ Cannabis Order Means for Patients and Clinicians
The medical cannabis Schedule III order is a major federal policy change, but it is not the same as new clinical proof. This Evidence Watch explains what the DOJ action may mean for research access, patient care, and regulated medical cannabis programs.…
Cannabis Rescheduling Is Not the Story People Think It Is
The cannabis rescheduling clinical impact is being widely misunderstood. While federal policy shifts from Schedule I to Schedule III signal progress, they do not define how cannabis should be used in medical care. This analysis clarifies what changes,…
Sick American Basketball Player Jailed in Indonesia Over Cannabis Gummies
International cannabis legal risks pose serious challenges for medical travelers. This case of a sick American basketball player jailed in Indonesia over cannabis gummies highlights these dangers. Patients must understand legal risks before traveling…
Medical Cannabis Authorization Linked to Modestly Higher Heart Failure Risk in Large Ontario Study
This Ontario cohort study examines medical cannabis cardiovascular safety, finding a modestly higher heart failure risk among authorized patients. The hazard ratio was 1.15, indicating a 15% increased risk for heart failure-related events. These findings…
Canadian Cannabis Legalization Linked to Tens of Thousands of Estimated Annual Deaths—But the Numbers Require Careful Scrutiny
Cannabis-associated health risks contribute to an estimated 28,000 to 30,000 premature deaths annually in Canada. These figures derive from population-attributable fraction modelling rather than direct causal attribution. Understanding…